Your browser version may not work well with NCBI's Web applications. More information here...
1: J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6.Click here to read Links
Comment on:
J Clin Oncol. 2007 Jun 20;25(18):2528-33.

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

Costa DB, Schumer ST, Tenen DG, Kobayashi S.

PMID: 18309959 [PubMed - indexed for MEDLINE]

Related Articles

Patient Drug Information
  • Gefitinib (Iressa®) Gefitinib is used to treat non-small cell lung cancer in people who have already been treated with certain other chemotherapy medications and have not improved or whose condition has worsened. Gefitinib has not been show...
    » read more ...
  • Erlotinib (Tarceva®) Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
    » read more ...